Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07214649

Organoids for Bile Leaks

Background: Bile leakage remains a major complication after hepatobiliary surgery and liver transplantation. While most cases are managed through standard radiologic or endoscopic interventions, a subset of patients fails to respond and may face recurrent interventions or even retransplantation. Recent advances in regenerative medicine, particularly the development of extrahepatic cholangiocyte organoids (ECOs), offer a promising alternative.

Objective: This prospective, 5-year study aims to evaluate the feasibility, safety, and efficacy of autologous ECO-based cell therapy to reconstruct bile ducts in patients with persistent bile leakage unresponsive to standard care.

Methods: Patients undergoing hepatobiliary or liver transplant surgery will have a biopsy of extrahepatic bile duct tissue collected perioperatively. The tissue will be processed and stored in a dedicated biobank. Upon development of a refractory bile leak, ECOs will be generated from the stored tissue and delivered to the site of injury through radiological or endoscopic routes, as decided by a multidisciplinary team. Success will be evaluated by resolution of leakage (radiologically or endoscopically) and absence of further intervention.

Significance: The use of patient-specific ECOs holds transformative potential. Organoids can be derived and expanded in vitro while maintaining cholangiocyte identity and function. Preclinical studies in murine and human models show successful engraftment and functional integration into biliary epithelium.

Expected Outcomes: This project aims to pioneer a novel, minimally invasive, personalized regenerative therapy for otherwise intractable biliary complications.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age over 18 years old
  • Undergone HPB surgical procedure with hepatic duct reconstruction
  • Presence of anastomotic bile leakage untreatable with radiological or endoscopic approach
  • Presence of bile duct specimen

Exclusion criteria

  • Age under 18 years old
  • Undergone HPB surgical procedure without hepatic duct reconstruction
  • Absence of anastomotic bile leakage untreatable with radiological or endoscopic approach
  • Absence of bile duct specimen

Treatment and study plan

Organoid-guided treatment

Biological

Engrafment of the Cholangiocyte Organoids in the common bile duct with leakage

Primary outcomes

  1. Treatment of the leaks

    Time frame: 1 week

    Absence of leak at radiological or endoscopic evaluation

Study contacts

Contact information is provided by the study sponsor or research team.

Marco M Pascale, MD

CONTACT

[email protected]

0039 3888264297

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

A Prospective Study Using Patient-Derived Extrahepatic Cholangiocyte Organoids for Refractory Bile Leaks

Acronym: ASCORB

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Oct 9, 2025
Registry last updated
Oct 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.